Background. Follicular dendritic cell sarcoma (FDCS) is a rare lymphoid neoplasm presenting in the head and neck. There are no pooled analyses of head and neck FDCS cases in the English language literature. Methods. A MEDLINE and PubMed review of cases from 1978 to February 2014 was performed. Demographics, clinicopathologic data, and outcomes were summarized. Results. We presented 2 patients and analyzed 97 cases. The mean age was 42.7 years (SD 5 16.3 years). Outcomes were available for 76 patients. Tumors 4 cm had better disease-free survival (63% vs 28% at 5 years; p 5 .0282). Locoregional recurrence was significantly less likely with surgery and radiation compared to surgery alone (15% vs 45%; p 5 .019) and in patients receiving a neck dissection (10% vs 43%; p 5 .046).
INTRODUCTION
Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm arising within lymphoid tissue, with only 400 cases reported in the English literature. [1] [2] [3] Follicular dendritic cells are nonmyeloid, nonphagocytic, innate immune cells found primarily in germinal centers of secondary lymphoid organs and characterized by CD21, CD35, R4/23, and KiM4 surface expression. 4 One of their main functions is to present antigens and immune complexes to B and T lymphocytes. Since its discovery in 1986, FDCS has continued to be a poorly understood clinical entity. The majority of FDCS literature, especially pertaining to the head and neck, consists of case reports and case series.
FDCS is characterized as intranodal or extranodal. Extranodal sites include the oropharynx, parapharyngeal space, neck soft tissues, thyroid, liver, kidney, and axial skeleton. [5] [6] [7] [8] [9] [10] [11] [12] [13] Overall, cervical lymph node groups are the most commonly involved sites. 13 Diagnosis of FDCS is challenging as approximately 50% of cases are misdiagnosed as undifferentiated carcinomas. 1, 14 Histopathologically, these malignancies are characterized by ovoid, polygonal, and spindle-shaped cells arranged in a whorling-type storiform pattern with admixed lymphocytes. 1, 15 Further complicating the issue, biopsies and fine-needle aspirates often contain necrotic or reactive lymphoid tissue, making the definitive diagnosis of FDCS challenging.
FDCS is assumed to be a low-grade neoplasm with the majority of patients surviving up to 10 years and beyond in most published reports. 1, 2, 5, 16 Prognostic factors for FDCS have not been systematically evaluated to date. Although surgical resection has been the mainstay of treatment for local disease, chemotherapy and radiation are often used as adjunctive treatments with limited evidence to guide these decisions. Indeed, the rarity of FDCS has precluded the type of clinical studies necessary to drive evidence-based adjuvant treatment of FDCS.
In the absence of such data, pooling outcomes from the available literature may serve to clarify clinicodemographic and prognostic trends. In this study, we present 2 new FDCS cases and objectively review treatment and prognosis of FDCS of the head and neck. Case 1 is the first FDCS arising in the mandible, whereas case 2 describes tonsillar FDCS with positive nodal disease.
Physical examination revealed scarring in the right retromolar trigone without cervical lymphadenopathy. An MRI showed an enhancing, expansile, lobulated 2.5-3 1.3-3 4.0-cm lesion in the body of the mandible extending to the right mandibular angle abutting the posterior molar dentition and partially extending through the buccal cortex ( Figure 1 ). For diagnostic purposes, the patient underwent dental extraction of tooth 30, wide local excision, and curettage of the cyst epithelium. The lesion had eroded through the lateral wall of the ramus. Pathology was notable for a cystic lesion of dense aggregates of rounded cells in a fascicular and whorled pattern mixed with lymphocytes, typical of that described for FDCS. 17 Immunohistochemical stains were positive for clusterin and CD21, partially positive for CD35 and CXCL13, and negative for p63, CK5, S100, MART-1, Melan-A, LCA, kappa, lambda, CD3, CD30, CD138, CD163, Alk-1, OSCAR, MUM-1, PAX5, CD4, CD2, and CD43, which are also consistent with FDCS. No suggested markers of poor prognosis (absence of lymphoplasmacytic response, tumor size >6 cm, atypia, or high mitotic count) were identified.
Staging positron emission tomography/CT identified intense uptake (standardized uptake value 5 15.83) in the right mandibular ramus near the third molar as well as mild uptake (standardized uptake value 5 2.97) in a right submandibular node. The patient underwent a right composite hemimandibulectomy with a right selective neck dissection of levels I through IV (Figure 2 ). Final pathology revealed negative resection margins. The lesion was morphologically identical to the biopsy material, with similarly spindled to ovoid cells arranged in a storiform pattern with scattered lymphocytes ( Figure 3A ; hematoxylin-eosin stain, original magnification 3100). On high power, the tumor cells had nuclei with mild atypia, prominent nucleoli, few mitoses, and a moderate amount of eosinophilic cytoplasm with indistinct cell borders ( Figure 3B ; hematoxylin-eosin stain, original magnification 3400). Immunohistochemical stains for CD21 and CD23 showed strong membranous reactivity in the tumor cells, confirming a follicular dendritic cell origin ( Figure 3C and 3D, respectively, hematoxylin-eosin stain, original magnification 3400). All 48 lymph nodes were negative for tumor.
The patient was evaluated by radiation oncology and the multidisciplinary consensus was to not treat further with adjuvant therapy. At 1-year follow-up, the patient has had no evidence of recurrent disease.
Case 2
A 32-year-old Hispanic man presented with a 10-week history of painless left-sided neck swelling. He denied dysphagia, hoarseness, and otalgia. Examination was significant for a firm, nonfixed 5 cm left neck mass, extending from level II to III and induration of the left tonsil. There was no evidence of other lesions in the nasopharynx, oropharynx, or larynx on nasopharyngolaryngoscopy. CT revealed a 3.0-3 3.0-cm left level II anterior neck mass compressing the internal jugular vein, as well as a 1.8-3 2.3-cm submucosal left tonsillar mass with central hypodensity consistent with fluid or necrosis. Fine-needle aspiration of the neck mass was consistent with a malignant neoplasm in a background of necrosis, possibly a poorly differentiated carcinoma. Biopsy of the left tonsil was negative for carcinoma. The patient underwent bilateral palatine tonsillectomy for diagnostic purposes. A staging positron emission tomography/CT was performed but did not reveal any distant metastases, indicating T2N2aM0 disease according to American Joint Committee on Cancer staging criteria for head and neck pharyngeal cancer. 18 He subsequently underwent a left lateral pharyngotomy, radical tonsillectomy, left selective neck dissection of levels II through V, and anterolateral free flap reconstruction. Final pathology revealed that additional tumor tissue was found in the left oropharynx infiltrating skeletal muscle, and 2 of 71 lymph nodes were positive for malignancy (largest measuring 7.0 cm). Postoperatively, he received chemoradiation. The radiation regimen was 66 Gy split into 33 fractions of 2 Gy to the left oropharynx and bilateral necks. He was initiated on a chemotherapy regimen of cyclophosphamide (350 mg/m 2 ) and topotecan (0.75 mg/m 2 on days 1-5). However, he developed radiation recall. He subsequently received gemcitabine (675 mg/m 2 on days 1 and 8) and docetaxel (75 mg/m 2 on day 8). Unfortunately, the patient developed lung and liver metastases 2 years later and was ultimately transitioned to palliative care.
METHODS
A MEDLINE and PubMed review of cases of FDCS of the head and neck from 1978 to February 2014 was conducted. Ninety-five previous cases of head and neck FDCS were identified in the English language literature, constituting a total of 97 cases including our own (Table  1) .
1,2,4,6-9,11,12,15-17,19-60 Information on patient demographics, location, tumor size, adjuvant therapies, recurrence, and mortality was recorded for analysis. Associations between clinicopathologic features, treatment methods, and outcomes were analyzed using chi-square testing. Analysis of variance, multiple analysis of variance, and t tests were conducted on quantitative data. Kaplan-Meier analysis was performed and Wilcox logrank testing was used to evaluate disease-free survival (DFS) and overall survival (OS). Statistical analyses were performed with STATA SE and Graphpad Prism software.
RESULTS

Clinical features
Demographic and clinicopathologic features of FDCS in the English language literature are summarized in Table 1 . The mean age at the time of presentation was 42.7 years (range, 9-76 years). Fifty-three percent of the patients were men. The mean tumor dimension was 4.5 cm.
The most common primary tumor sites were the cervical lymph nodes (40%; 39 of 97), oropharynx (24%; 23 of 97), and neck soft tissue (10%; 10 of 97). Interestingly, tumors located in the soft tissue of the neck presented at the youngest age (30.1 6 16.5 years; mean 6 SD) and those located in the thyroid presented at the most advanced age (61.5 6 17.0 years; p 5 .0276). Tumors in the soft tissue of the neck presented with the largest tumors (7.0 6 4.6 cm) and tumors in the thyroid presented with the smallest (1.8 6 0.4 cm).
In total, 7 patients (7%) presented with regional metastases to the cervical lymph nodes and 2 patients (2%) presented with distant lung metastases. Of note, oropharyngeal lesions were significantly more likely to present with regional metastases compared to nonoropharyngeal lesions (including FDCS of the cervical lymph nodes, 17% vs 4%; p 5 .031).
Treatment
Various treatment approaches exist for FDCS ( Table 2) . The majority of patients with available treatment data (91 of 97 patients) received surgery alone (57%; 52 of 91). Thirteen of 91 patients (14%) underwent a neck dissection along with primary resection. Twenty-three percent of the patients (21 of 91) received surgery with adjuvant radiation (mean and median doses were 5345 and 5625 cGy, respectively; reported in 13 cases). The remaining patients were treated with surgery and adjuvant chemotherapy (7%; 6 of 91), surgery and chemoradiation (5%; 5 of 91), chemoradiation (4%; 4 of 91), and chemotherapy only (3%; 3 of 91). Two of the 4 patients receiving chemoradiation had tumors >8 cm, 39, 53 and 1 of the 4 presented with a metastatic lesion in the lung. 23 Common therapeutic agents included gemcitabine, 53 cisplatin and docetaxel, 2 ifosfamide, carboplatin, and etoposide, 2,4 and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).
9,21,39
Clinical outcomes
There was a wide range in length of follow-up among the reported case series. The mean follow-up was 3.0 years (SD 5 2.9 years) and follow-up data were A total of 97 cases were identified in the English language literature. The mean age at presentation was 42.7 6 16.3 years (range, 9-76). Seven patients presented with regional metastases and two with distant metastases. The mean length of the tumor's longest dimension was 4.5 6 3.2 cm. Thirty-six percent of tumors were >4 cm in size.
unavailable for 22% of patients (21 of 97; Table 2 ). Therefore, analysis of clinical outcomes was limited to 76 of 97 patients (78%). Among studies with available survival and recurrence data, 65% of patients had no evidence of disease, 21% were alive with disease, and 14% had died of their disease. Kaplan-Meier survival curves for all cases are shown in Figure 4A . OS was 91% at 2 years and 81% at 5 years. The incidence of local, regional, locoregional, and distant recurrence was 31%, 5%, 38%, and 7%, respectively. The mean time to recurrence of any type was 2.7 years (SD 5 3.4 years). DFS was 64% at 2 years and 34% at 5 years. There was no association between tumor site, tumor size, or presence of regional metastases and the decision to treat with radiation or chemotherapy. The locoregional recurrence rate was significantly lower in patients receiving a neck dissection and in those receiving adjuvant radiotherapy after resection of the primary tumor, as discussed below.
Clinicopathologic characteristics and outcomes
There was no significant relationship among age, sex, or metastases at presentation on the locoregional recurrence rate (p 5 .688, p 5 .217, and p 5 .453, respectively). Lesions in the oropharynx were significantly more likely to present with regional metastases (17% vs 4%; p 5 .031), yet, they were not more likely to have either locoregional or distal recurrence (20% vs 43%; p 5 .158). However, patients with oropharyngeal lesions had significantly better DFS than patients with tumors at other sites (61% vs 26% at 5 years; p 5 .0445; Figure 4B ). There was also a relation between tumor size and DFS. Patients with tumor sizes 4 cm had significantly better DFS compared with patients with tumor sizes >4 cm (63% vs 28% at 5 years; p 5 .0282; Figure 4C ).
Adjuvant therapies and clinical outcomes
There is currently no consensus on the specific role of chemotherapy and radiation in FDCS management. Therefore, we evaluated relationships between therapeutic modalities and clinical outcomes. Patients were categorized into groups as follows: (1) surgery only; (2) surgery 1 chemoradiotherapy; (3) surgery 1 chemotherapy; (4) surgery 1 chemoradiotherapy; (5) chemoradiotherapy; and (6) chemotherapy only. Specific outcome data for each treatment group are shown in Table 2 .
Only the first 2 categories (surgery alone and surgery plus chemoradiotherapy) had enough patients for meaningful statistical comparisons. When comparing surgery alone (n 5 52) versus surgery plus chemoradiotherapy (n 5 21), tumors were significantly less likely to recur locoregionally in the surgery plus chemoradiotherapy group (15% vs 45%; p 5 .019; Table 2 ). The surgery alone group and the surgery plus chemoradiotherapy group were not different at baseline with regard to sex distribution (p 5 .854), age (p 5 .675), initial site (p 5 .190), presence of regional metastasis (p 5 .386), percentage of tumors >4 cm (p 5 .508), and tumor size (p 5 .931). However, there was no difference between these 2 treatment groups in the time to the first recurrence (p 5 .7956), death rate (p 5 .366), DFS (p 5 .3070), or OS (p 5 .7117; Table 2 ).
Chemotherapy was not associated with improved locoregional recurrence (50% vs 37%; p 5 .379). However, neck dissection did confer a statistically significant advantage in locoregional recurrence rate. Specifically, 10% of the patients (1 of 10) receiving neck dissection developed locoregional recurrence compared to 43% of the patients (28 of 65) who did not receive a neck dissection (p 5 .046). However, neck dissection was not associated with better DFS (p 5 .7364) or OS (p 5 .8964). Abbreviations: OS, overall survival; DFS, disease-free survival. Local recurrence was 31% (27/76), regional recurrence was 5% (4/76), and mortality rate was 14% (10/71). Two-year and 5-year OS was 91% and 81%, respectively. Two-year and 5-year DFS was 64% and 34%, respectively. Surgery alone was the most common intervention, followed by surgery plus adjuvant radiation. There was a statistically significant benefit to surgery plus radiation in local recurrence rate (15% vs 45%; p 5 .019). * Indicates p 5 .019 in local recurrence between surgery alone and surgery 1 radiotherapy. Hyphen (-) indicates no follow-up data reported.
DISCUSSION
FDCS is a rare malignancy of lymphoid tissue that is thought to behave similarly to a low-grade sarcoma rather than a lymphoma. 13 Because of its clinical obscurity, a paucity of evidence is available to guide clinical decisionmaking in the management of head and neck FDCS. Currently, there exist neither multicenter prospective studies nor pooled analyses focusing on FDCS cases of the head and neck in the English literature. In an attempt to more fully and objectively characterize this clinical entity, we conducted a MEDLINE and PubMed search of the available English literature. Including the 2 cases from our institution, we identified 97 cases meeting criteria for analysis.
Our analysis revealed that, in accordance with previous literature, the mean age was 42.7 years and the sex distribution was essentially 1:1. We found that the mean tumor size was 4.5 cm. This is consistent with another report that examined extranodal FDCS tumors, which reviewed 46 cases at 10 different sites. 61 As expected, the most common site was the cervical lymph nodes, although FDCS presented with notable frequency in the nasopharynx, oropharynx, oral cavity, and thyroid gland. Literature-reported local recurrence rates range from 23% to 43%, metastases rates average approximately 21%, and mortality rates range from 3% to 7%. 5, 9, 61 We found the locoregional recurrence rate and mortality rate to be 38% and 14%, respectively. Two and 5-year DFS rates were 64% and 34%, respectively, and the 2-year and 5-year OS rates were 91% and 81%, respectively. These outcome data suggest that FDCS indeed has a prognosis akin to a low-grade sarcoma, as suggested by previous literature. 2, 4 Clinical and histologic diagnosis of FDCS is challenging. Although the tumor morphologies in cases 1 and 2 were consistent with prior descriptions of FDCS, 17 correct diagnosis is difficult because of the infrequency with which FDCS is encountered in the head and neck. In addition, many other neoplasms, including sarcomatoid (spindle cell) carcinomas, melanomas, lymphomas, and mesenchymal tumors, can have a whorling pattern with intermixed lymphocytes. In fact, 2 of 3 cases in a series of FDCS in the head and neck region by Biddle et al 8 were initially misdiagnosed. Given the mandibular location of case 1, it should be noted that the morphology of FDCS is not similar to that typically seen in odontogenic lesions. Immunohistochemical stains can be helpful in distinguishing FDCS from other spindle-cell neoplasms. Specifically, CD21 and CD23 are markers of follicular dendritic cells that have been shown to be positive in the majority of FDCS specimens. 8, 62 Additionally, clusterin has been found to be a sensitive and specific stain for FDCS. 63, 64 A study of 14 FDCS cases and 188 cases of 15 different types of spindle-cell tumors found clusterin positivity to have a sensitivity of 100% and a specificity of 93%. 64 Studies have also shown that FDCS is not immunoreactive for cytokeratins and CD45, 8, 65 which would argue against alternative diagnoses of a sarcomatoid (spindle cell) carcinoma or lymphoma, respectively. Negative S100 staining has been reported in the majority of cases, 8, 64, 65 which helps rule out a diagnosis of melanoma.
Previous literature has concluded that patients with localized disease have significantly better OS compared with patients with distant disease. 2 Young age, absence of lymphoplasmacytic response, tumor size >6 cm, and high mitotic count (>5 per field) have been significantly On Kaplan-Meier analysis, two-year and five-year disease-free survival was 64% and 34%, respectively (Fig. 4A) . Two-year and five-year overall survival was 91% and 81%, respectively (Fig.  4A) . Tumors with a primary location in the oropharynx had statistically significantly better disease-free survival than tumors with a primary location outside the oropharynx (p 5 0.0445; Fig. 4B ). Overall survival was 75% vs. 61% at 2 years and disease-free survival was 61% vs. 26% at 5 years (Fig. 4B ). Tumors less than or equal to 4 cm in size had statistically significantly better disease-free survival than tumors greater than 4 cm in size (p 5 0.0282; Fig. 4C ). Overall survival was 72% vs. 37% at 2 years and disease-free survival was 63% vs. 28% at 5 years (Fig. 4C ).
associated with a poor prognosis in the literature. 2 We investigated whether demographic and clinicopathologic factors had prognostic implications. One interesting finding was that FDCS tumors located in the oropharynx were significantly more likely to present with regional metastases than tumors located outside of the oropharynx (17% vs 4%; p 5 .031). A potential explanation for this finding is that lymphatic spread from the oropharynx is more easily accomplished because of the rich and extensive lymphatic network draining this region. Interestingly, oropharyngeal location was associated with significantly improved DFS (p 5 .0445), despite this higher rate of regional metastases at presentation. Additionally, we found that tumors >4 cm in size seemed to be more aggressive than those 4 cm, with DFS being 28% versus 63% at 5 years (p 5 .0282). Of note, tumor size is a prognostic factor in soft tissue sarcoma as well, with tumor size >5 cm placing patients in a T2 versus T1 classification according to American Joint Committee on Cancer criteria. 18 Therefore, patients with large FDCS tumors should be considered for more aggressive treatment.
Surgical resection has been the mainstay of treatment for all FDCS sites. However, there seems to be no consensus regarding indication for neck dissection. In our analysis, at least 46 patients were candidates for neck dissection (39 with primary tumors in the neck plus 7 with regional metastases at presentation); yet only 13 neck dissections were performed. Of the 10 patients who underwent neck dissection who were followed longitudinally, only 1 (10%) developed locoregional recurrence compared to 43% (28 of 65) in patients who did not receive a neck dissection (p 5 .046). This suggests that patients with primaries in the neck and patients with regional metastasis should be considered for neck dissection.
Adjuvant chemotherapy and radiotherapy are often used for large tumors or those with high-grade features, such as cytologic atypia. 66 However, previous literature has not demonstrated outcome benefits from adjuvant therapies. 1, 16 Indeed, a recent pooled analysis by Saygin et al 2 found no benefit of surgery with adjuvant radiotherapy compared to surgery alone, although this analysis included tumors outside of the head and neck. Because there is no consensus on the role of adjuvant radiation for FDCS management, one of our primary interests was to compare outcomes in patients receiving surgery alone to patients receiving surgery plus radiation. Although the majority of patients in our analyses received surgical resection only (57%), 23% received surgery plus radiotherapy. Interestingly, we noted that patients receiving surgery plus radiation had a significantly lower locoregional recurrence rate than patients receiving surgery alone (15% vs 45%; p 5 .019). The 2 groups were not significantly different at baseline with regard to age, sex distribution, presence of regional metastasis, or tumor size. Therefore, it seems that chemoradiotherapy should be considered for patients with FDCS. Although it is difficult to make strong recommendations about high-risk groups in which chemoradiotherapy may be particularly advantageous, patients with tumors >4 cm were found in our analysis to have worse DFS than patients with smaller tumors, and, as such, should receive consideration for adjuvant chemoradiotherapy. Radiation may also be considered in patients with close resection margins (<1 cm), which is a recommendation based on National Comprehensive Cancer Network clinical practice guidelines for soft tissue sarcoma. 67 Unfortunately, our attempt to identify subgroups of patients with FDCS who may be better served with adjuvant chemoradiotherapy was precluded by our sample size. Larger multicenter prospective studies would more effectively evaluate adjuvant therapies, yet are difficult to perform for a tumor as rare as FDCS. A more practical solution may be expansion of the American Society of Clinical Oncology's CancerLinQ health information technology program, which collects electronic medical record data in real-time for large-scale clinical studies. 68 Although this program is currently in a prototype stage focused on breast cancer, expansion into additional oncologic fields may prove especially helpful in guiding the management of rare tumors, such as FDCS.
Currently, chemotherapy is included in the treatment of most cases of metastatic FDCS, although there is no consensus on the most effective regimen. CHOP and ifosfamide, carboplatin, and etoposide protocols are the most commonly chosen chemotherapeutic regimens, 30 which might be due to their success in treating nodal malignancies, such as intermediate grade lymphomas. 2 However, recent studies have elucidated that follicular dendritic cells have a vascular stromal rather than a hematopoietic origin, a finding that is consistent with their clinical behavior and prognosis being similar to low-intermediate grade soft tissue sarcomas. 69, 70 Therefore, treatment with agents better suited to mesenchymal stromal tumors rather than hematopoietic malignancies may be more appropriate. Indeed, Conry 69 reported 2 cases of FDCS metastatic to the liver that exhibited durable objective responses to gemcitabine and docetaxel. Khalid and Folman 71 also reported a partial response of hepatic FDCS to gemcitabine after failure of the CHOP protocol. Addition of imatinib, a tyrosine kinase inhibitor, to gemcitabine and cisplatin for a case of metastatic FDCS resulted in complete pathological remission. 72 Our study had several limitations. Complete follow-up data was unavailable for 22% of patients. We only identified 18 patients who received chemotherapy, which precluded statistical analyses on the impact of chemotherapy on survival. In addition, histologic features were inconsistently reported. Thus, we were unable to assess for correlation of immunophenotypic markers and histologic features with clinical outcome.
CONCLUSION
FDCS is a low-grade malignancy of lymphoid tissue that presents in the head and neck. In addition to presenting the first known case of FDCS in a mandible, we conducted a MEDLINE and PubMed review and identified 95 additional cases of head and neck FDCS in the English literature. Statistical analyses revealed that oropharyngeal tumors were more likely to present with regional metastases. Tumors >4 cm in size had significantly worse DFS. Patients who received surgery plus radiation compared to surgery alone, and patients who had a neck dissection, were significantly less likely to recur locoregionally, although DFS and OS were not significantly improved.
Our findings may inform clinicians treating and counseling patients with this rare entity. Radiotherapy should be considered in patients with FDCS, specifically those with tumor sizes >4 cm. Neck dissection should be considered in patients with locoregional metastases. Unfortunately, the limitations of our study design preclude us from making stronger recommendations. Future health information technologies may better aggregate and analyze cancer data, building on meta-analyses and preclinical laboratory studies to more fully understand the biology, behavior, and treatment responses in head and neck FDCS.
